No Data
No Data
Yahong Medicine (688176.SH): has repurchased 1.0685% of the shares cumulatively.
On July 3rd, Gelonhui reported that Yahong Medicine (688176.SH) has cumulatively repurchased 6,090,403 shares through centralized bidding trading as of July 3, 2024, accounting for 1.0685% of the total equity of the company. Compared with the previous disclosure, the proportion has increased by 0.4419%. The highest price for repurchase transactions was RMB 6.73 per share, the lowest price was RMB 5.08 per share, and the total amount paid was RMB 36,196,800 (excluding stamp duty, transaction commissions, and other transaction costs).
Yahong Pharmacy (688176.SH): the actual controller and financial person in charge have completed the shareholding, costing 4 million yuan.
Yahong Pharmaceutical (688176.SH) announced that as of July 2, 2024, the company's controlling shareholder and actual controller...
Yahong Meditech to Trial Drug Against Amoebae Infection
Yahong Pharmaceutical (688176.SH): APL-1202 clinical trial application has been approved by the National Medical Products Administration.
On June 24th, Gelunhui reported that Jiangsu Yahong Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "company") has received the drug clinical trial approval notice issued by the National Medical Products Administration (NMPA) for APL-1202, which is used to treat Free-living Amoebae (FLA) infection. This study is an evaluation of the use of hydroxychloroquine tablets (APL-1202) to treat Free-living Amoebae.
Yahong Pharmaceutical (688176.SH): The marketing application for APL-1702 (Hexyl Hydrochloride Ointment Photodynamic Therapy System) was accepted
Gelonghui, May 12 | Yahong Pharmaceutical (688176.SH) announced that the company recently received the “Notice of Acceptance” approved and issued by the National Drug Administration (NMPA). The company's product APL-1702 (generic name: aminonovalerate ointment photodynamic therapy system) is intended to treat high-grade cervical squamous intraepithelial lesion (HSIL) patients aged 18 and above to eliminate cancer in situ (HSIL) Accepted. APL-17
Yahong Pharmaceutical (688176.SH): A total of 0.6266% of shares have been repurchased
Gelonghui, May 6, 丨 Yahong Pharmaceutical (688176.SH) announced that as of April 30, 2024, the company had repurchased a total of 3,571,534 shares, accounting for 0.6266% of the company's total share capital. The highest price of the repurchase transaction was RMB 6.73 yuan/share, the lowest price was RMB 5.33 yuan/share, and the total capital paid was RMB 22.9833 million (excluding transaction fees such as stamp duty and transaction fees).
No Data